

AD Immunotherapy : Towards a disease modification therapy in Alzheimer disease via targeting Tau protein with monoclonal antibodies

<https://neurodegenerationresearch.eu/survey/ad-immunotherapy-towards-a-disease-modification-therapy-in-alzheimer-disease-via-targeting-tau-protein-with-monoclonal-antibodies/>

Principal Investigators

JANSSEN PHARMACEUTICA

Institution

JANSSEN PHARMACEUTICA

Contact information of lead PI

Country

Belgium

Title of project or programme

AD Immunotherapy : Towards a disease modification therapy in Alzheimer disease via targeting Tau protein with monoclonal antibodies

Source of funding information

Flanders Innovation & Entrepreneurship

Total sum awarded (Euro)

€ 284,943

Start date of award

01/05/2016

Total duration of award in years

2

Keywords

Research Abstract

Further information available at:

Types:

Investments < €500k

Member States:

Belgium

Diseases:

N/A

Years:

2016

Database Categories:

N/A

Database Tags:

N/A